Therma Bright (TSE:THRM) has released an update.
Therma Bright Inc., a medical device developer, has successfully raised $1 million CAD through private capital to invest in its innovative Digital Cough Analyzer and InStatin Inc., and to manage debts and operational expenses. The company anticipates approval for HCPCS and CPT codes for its Venowave VW5 device, targeting a deep vein thrombosis market projected to grow significantly by 2032. Additionally, Therma Bright is advancing with FDA discussions for its AI-powered Digital Cough Analyzer and is progressing with investments in stroke and respiratory treatment technologies.
For further insights into TSE:THRM stock, check out TipRanks’ Stock Analysis page.
